Skip to content

Clinical trials

Phase 1 Alzheimer Disease trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Alzheimer Disease Phase: Phase 1 Country / region: United States Clear all

298 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20032
20044
20053
20065
200714
200815
200927
201019
20118
201211
201312
201411
201517
201617
201711
201812
201916
202013
202117
202215
202313
202413
20256
202612

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed215
Terminated32
Recruiting22
Active, not recruiting12
Not yet recruiting7
Unknown status6
Withdrawn4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company19
Institute for Neurodegenerative Disorders18
Pfizer17
Avid Radiopharmaceuticals12
Bristol-Myers Squibb10
Molecular NeuroImaging9
Eisai Inc.6
Merck Sharp & Dohme LLC6
Wyeth is now a wholly owned subsidiary of Pfizer6
AbbVie5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Alzheimer Disease298
Cognitive Dysfunction36
Dementia26
Parkinson Disease12
Huntington Disease9
Supranuclear Palsy, Progressive7
Central Nervous System Diseases6
Neurodegenerative Diseases6
Tauopathies6
Multiple Sclerosis4

Trials

Showing 1 to 25 of 298. Each trial links to its page on Pharma Observatory.

198 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.